GlassScriptPhysician profile
Amyjo Wallingford
NPI 1063027183
$6,772.35
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $567 · 2022: $1,671 · 2023: $2,498 · 2024: $2,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,534.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,499.23 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $1,208.88 | 2021-2024 | Fasenra, Breztri, Tezspire |
| Regeneron Healthcare Solutions, INC. | $639.45 | 2021-2024 | Dupixent |
| Biocryst US Sales Co., LLC | $551.82 | 2021-2024 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $531.26 | 2021-2024 | Hyqvia, Cuvitru, Takhzyro |
| Csl Behring | $314.28 | 2022-2024 | Hizentra, Haegarda |
| Pharming Healthcare, INC. | $295.33 | 2021-2024 | Ruconest |
| Amgen INC. | $189.19 | 2021-2024 | Tezspire, Actimmune |
| Abbvie INC. | $173.15 | 2022-2024 | |
| Grifols USA, LLC | $166.76 | 2022-2023 | Xembify, Prolastin-C Liquid |
| Genentech USA, INC. | $163.77 | 2021-2024 | Xolair |
| Glaxosmithkline, LLC. | $159.24 | 2022-2024 | Trelegy Ellipta, Nucala |
| Optinose US, INC. | $123.55 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $121.98 | 2022-2024 | |
| Kaleo, INC. | $102.87 | 2021-2024 | Auvi-Q |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $71.54 | 2021-2024 | Opzelura |
| Electromed, INC. | $69.02 | 2022 | |
| Pfizer INC. | $59.25 | 2022-2024 | |
| Leo Pharma INC. | $55.31 | 2022-2023 | Adbry |
| Blueprint Medicines Corporation | $54.55 | 2022-2024 | Ayvakit |
| Hospira, INC. | $49.74 | 2024 | |
| Aimmune Therapeutics, INC. | $39.02 | 2021-2022 | |
| Octapharma USA, INC. | $35.43 | 2022-2024 | Octagam Immune Globulin (Human) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.83 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $16.52 | 2022 | |
| Mylan Specialty L.P. | $16.42 | 2024 | Yupelri |
| Adma Biomanufacturing LLC | $15.47 | 2021 | |
| Alk-Abello, INC | $14.68 | 2022 | |
| Hikma Pharmaceuticals USA | $12.81 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amyjo Wallingford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.